Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625812 | 0.87 | PTGER4 (0.66) | PTGER4TP53KMT2ANTRK1NTRK2 | |
| SCHEMBL3955699 | 0.87 | PTGER4 (0.51) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL23844020 | 0.85 | PTGER4 (0.49) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL6018506 | 0.85 | PTGER4 (0.52) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL5999659 | 0.84 | PTGER4 (0.63) | PTGER4TP53NTRK1NTRK2MAPT | |
| SCHEMBL7594108 | 0.84 | PTGER4 (0.50) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL6018725 | 0.84 | PTGER4 (0.48) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL7170969 | 0.82 | PTGER4 (0.45) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL7595033 | 0.82 | PTGER4 (0.48) | PTGER4TP53KMT2AAGTR2AGTR1 | |
| SCHEMBL7594246 | 0.82 | PTGER4 (0.48) | PTGER4TP53KMT2AAGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885TP53 4389/4885KMT2A 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.